TY - JOUR
T1 - Less frequent and less severe flu-like syndrome in interferon beta-1a treated multiple sclerosis patients with at least One allele bearing the G>C polymorphism at position -174 of the IL-6 promoter gene
AU - Bertoli, Diego
AU - Serana, Federico
AU - Sottini, Alessandra
AU - Cordioli, Cinzia
AU - Maimone, Davide
AU - Amato, Maria Pia
AU - Centonze, Diego
AU - Florio, Ciro
AU - Puma, Elisa
AU - Capra, Ruggero
AU - Imberti, Luisa
PY - 2015/8/18
Y1 - 2015/8/18
N2 - One of the most common adverse event of interferon beta (IFNβ) therapy for multiple sclerosis is flu-like syndrome (FLS), which has been reportedly related to increased levels of cytokines such as interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Average cytokine levels can be affected by single nucleotide polymorphism in the gene promoter regions. To investigate whether IL-6-174 G>C and TNF-α -376 G>A polymorphisms could be correlated to the incidence of FLS, and whether an anti-inflammatory/antipyretic therapy may influence FLS development, a prospective observational study was performed in 190 treatment naive, multiple sclerosis patients who started IM IFNβ-1a 30mcg once weekly. The identification of IL-6-174 G>C and TNF-α -376 G>A polymorphisms was achieved by performing an amplification-refractory mutation system. Serum IL-6 levels were measured using enzyme-linked immunosorbent assay in blood samples taken before therapy and then after the first and last IFNβ-1a injection of the follow-up. FLS-related symptoms were recorded by patients once per week during the first 12 weeks of therapy into a self-reported diary. We found that patients carrying at least one copy of the C allele at position -174 in the promoter of IL-6 gene produced lower levels of IL-6 and were less prone to develop FLS, which was also less severe. On the contrary, the polymorphism of TNF-α had no effect on FLS. Patients taking the first dose of anti-inflammatory/antipyretic therapy in the peri-injection period (within 1 hour) experienced a reduced FLS severity. In conclusion, the study of IL-6-174 G>C polymorphism would allow the identification of patients lacking the C nucleotide on both alleles who are at risk of a more severe FLS, and may be addressed to a timely and stronger anti-inflammatory/antipyretic therapy for a more effective FLS prevention.
AB - One of the most common adverse event of interferon beta (IFNβ) therapy for multiple sclerosis is flu-like syndrome (FLS), which has been reportedly related to increased levels of cytokines such as interleukin 6 (IL-6) and tumor necrosis factor-alpha (TNF-α). Average cytokine levels can be affected by single nucleotide polymorphism in the gene promoter regions. To investigate whether IL-6-174 G>C and TNF-α -376 G>A polymorphisms could be correlated to the incidence of FLS, and whether an anti-inflammatory/antipyretic therapy may influence FLS development, a prospective observational study was performed in 190 treatment naive, multiple sclerosis patients who started IM IFNβ-1a 30mcg once weekly. The identification of IL-6-174 G>C and TNF-α -376 G>A polymorphisms was achieved by performing an amplification-refractory mutation system. Serum IL-6 levels were measured using enzyme-linked immunosorbent assay in blood samples taken before therapy and then after the first and last IFNβ-1a injection of the follow-up. FLS-related symptoms were recorded by patients once per week during the first 12 weeks of therapy into a self-reported diary. We found that patients carrying at least one copy of the C allele at position -174 in the promoter of IL-6 gene produced lower levels of IL-6 and were less prone to develop FLS, which was also less severe. On the contrary, the polymorphism of TNF-α had no effect on FLS. Patients taking the first dose of anti-inflammatory/antipyretic therapy in the peri-injection period (within 1 hour) experienced a reduced FLS severity. In conclusion, the study of IL-6-174 G>C polymorphism would allow the identification of patients lacking the C nucleotide on both alleles who are at risk of a more severe FLS, and may be addressed to a timely and stronger anti-inflammatory/antipyretic therapy for a more effective FLS prevention.
UR - http://www.scopus.com/inward/record.url?scp=84942636532&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942636532&partnerID=8YFLogxK
U2 - 10.1371/journal.pone.0135441
DO - 10.1371/journal.pone.0135441
M3 - Article
AN - SCOPUS:84942636532
VL - 10
JO - PLoS One
JF - PLoS One
SN - 1932-6203
IS - 8
M1 - e0135441
ER -